Advanced search
Publication Cover
Expert Review of Neurotherapeutics Volume 4, 2004 - Issue 1
Submit an article Journal homepage
396
Views
26
CrossRef citations to date
0
Altmetric
Drug Evaluation

Botulinum toxin type A (Botox®) in the treatment of migraine and other headaches

B Todd Troost Department of Neurology, Wake Forest University School of Medicine, Medical Center Boulevard, Winston-Salem, NC 27157, USA. [email protected]
Pages 27-31 | Published online: 10 Jan 2014

References

  • Castillo J, Mulioz P, Guitera V, Pascual J. Epidemiology of chronic daily headache in the general population. Headache 39, 190–196 (1999).
  • Olesen J. Headache Classification Committee of the International Headache Society. Classification and diagnostic criteria for headache disorders, cranial neuralgia and facial pain. Cephalalgia 24 (Suppl. 1), 1–160 (2004).
  • ••The new 2004 classification of headache.
  • Lipton RB, Stewart WF, Diamond S, Diamond ML, Reed M. Prevalence and burden of migraine in the United States: data from the American Migraine Study II. Headache 41,646–657 (2001).
  • Rasmussen BK, Jensen R, Schroll M. Epidemiology of headache in a general population: a prevalence study. j Clin. Epidemiol 44, 1147–1157 (1991).
  • Lipton RB, Stewart WF. Migraine headaches: epidemiology and comorbidity. Gun. Neurosci. 5, 2–9 (1998).
  • Hu XH, Markson LE, Lipton RB, Stewart WE Berger ML. Burden of migraine in the United States: disability and economic costs. Awn Intern. Meci 159,813–818 (1999).
  • Ramadan NM, Silberstein S, Freitag FG, Gilbert TT, Frishberg BM. Evidence-based guidelines for migraine headache in the primary care setting: Pharmacological management for prevention of migraine. Am. Acad. Neural. (2000).
  • Snow V, Weiss K, Wall EM, Mottur-Pilson C for the American Academy of Family Physicians and the American College of Physicians — American Society of Internal Medicine. Pharmacologic management of acute attacks of migraine and prevention of migraine headache. Ann. Intern. Med. 137, 840–849 (2002).
  • Anonymous. Standards of care for headache diagnosis and treatment. National Headache Foundation, Chicago, IL, USA (2001).
  • Freitag FG, Collins SD, Carlson HA et al for the Depakote ER Migraine Study Group. A randomized trial of divalproex sodium extended-release tablets in migraine prophylaxis. Neurology58, 1652–1659 (2002).
  • Freitag F. Topiramate prophylaxis in patients suffering from migraine with aura: results from a randomized, double-blind, placebo-controlled trial. Presentation at the 14th Migraine Trust International Symposium, London, UK, 23–26 September (2002).
  • Silberstein SD. Efficacy and safety of topiramate in migraine prevention: a dose-ranging, placebo-controlled, double-blind, multicentered study. Presentation at the 14th Migraine Trust International Symposium, London, UK, 23–26 September (2002).
  • Silberstein SD, Lipton RB. Chronic daily headache, including transformed migraine, chronic tension-type headache and medication overuse. In: friblIT's Headache and Other I-kad Pain. Silberstein SD, Dalessio DJ, Lipton RB (Eds). Oxford University Press, Oxford, UK, 247–282 (2001).
  • Goadsby PJ, Lipton RB, Ferrari MD. Migraine? Current understanding and treatment. N Engl. I Med. 346,257-270 (2002). Excellent review of the current pathophysiology of migraine.
  • Dodick DW. Botulinum neurotoxin. Headache 43 (Suppl. 1), S25—S33 (2003).
  • Binder WJ, Brin ME, Blitzer A, Schoenrock LD, Pogoda JM. Botulinum toxin type A (Botox) for treatment of migraine headaches: an open-label study. Otolaryngol Head Neck Surg. 123,669–676 (2000).
  • Silberstein S, Mathew N, Saper J, Jenkins S. Botulinum toxin type A as a migraine preventive treatment. Headache 40(6), 445–450 (2000).
  • Evers S, Rahmann A, Vollmer-Haase J, Husstedt IW. Treatment of headache with botulinum toxin A — a review according to evidence-based medicine criteria. Cephalalgia 22(9), 699–710 (2002).
  • Troost BT Botulinum toxin type A (Botox)
  • •therapy for intractable headache. Headache 42(5), 435 (2002).
  • Troost BT, Rosenberg JR, Wiles R Improvement in intractable headache with repeated botulinum toxin type A treatment. Neurology 60 (5 Suppl. 1), A323 (2003).
  • Freitag FG. Preventative treatment for migraine and tension-type headaches: do drugs having effects on muscle spasm and tone have a role? CNS Drugs17 (6), 373–381 (2003).
  • Guyuron B, Tucker T, Davis J. Surgical treatment of migraine headaches. Plast. Reconstc Surg. 109(7), 2183–2189 (2002).
  • Eross EJ, Dodick DW. The effects of botulinum toxin type A on disability in episodic and chronic migraine. Neumlogy 58(7 Suppl. 3), A497 (2002).
  • Mauskop A. Long-term use of botulinum toxin type A in the treatment of headaches. Neurology58 (7 Suppl. 3), A497 (2002).
  • Relja MA, Klepac N. Botulinum toxin type A reduces acute medication (triptans) use in migraine patients. Neurology60(5 Suppl. 1), A321 (2003).
  • Blumenfeld A. Botulinum toxin type A as an effective prophylactic treatment in primary headache disorders. Headache 43(8), 853–860 (2003). Key article on the use of botulinum toxin type A in the treatment of primary headache disorders.
  • Mathew N, Kallasarn J, Kaupp A, Meadors L. 'Disease Modification' in chronic migraine with botulinum toxin type A: long-term experience. Ikadache 42 (5), 454 (2002).
  • Scott AB. Botulinum toxin treatment of strabismus. American Academy of Ophthamology, Focal Points 1989. Clin. Mod. Ophthalmol 2(12), (1989).
  • Arthurs B, Flanders M, Codere F, Gauthier S, Dresner S, Stone L. Treatment of blepharospasm with medication, surgery and type A botulinum toxin. Can. Ophthalmol 22,24–28 (1987).
  • Jankovic J, Orman J. Botulinum A toxin for cranial-cervical dystonia: a double-blind, placebo-controlled study. Neurology 37,616–623 (1987).
  • Evans RW, Blumenfeld A. Botulinum toxin injections for headache. Headache 43, 682–685 (2003).
  • Greene P, Kang U, Fahn S, Brin M, Moskowitz C, Raster E. Double-blind, placebo-controlled trial of botulinum toxin injections for the treatment of spasmodic torticollis. Neurology40,1213–1218 (1990).
  • Jankovic J, Schwartz K. Botulinum toxin injections for cervical dystonia. Neurology 40,277–280 (1990).
  • Naumann M, Yakovleff A, Durif E A randomized, double-masked, crossover comparison of the efficacy and safety of botulinum toxin type A produced from the original bulk toxin source and current bulk toxin source for the treatment of cervical dystonia. Neurology249(1), 57–63 (2002).
  • Brashear A, Gordon ME, Elovic E et al Intramuscular injection of botulinum toxin for the treatment of wrist and finger spasticity after a stroke. N Eng/. I Med. 347,395–400 (2002).
  • Ishikawa H, Mitsui Y, Yoshitomi T et al Presynaptic effects of botulinum toxin type A on the neuronally evoked response of albino and pigmented rabbit iris sphincter and dilator muscles. Jpnj Ophthalmol 44, 106–109 (2000).
  • Welch MJ, Purkiss JR, Foster KA. Sensitivity of embryonic rat dorsal root ganglia neurons to Clostridium botulinum neurotoxins. Toxicology38, 245–258 (2000).
  • Aoki KR. Evidence for antinociceptive
  • •activity of botulinum toxin type A in pain management. Headache 43(Suppl. 1), S9—S15 (2003).
  • Dolly O. synaptic transmission: inhibition of neurotransmitter release by botulinum toxins. Headache 43\(Suppl. 1), S16—S24 (2003).
  • Silberstein SD. Neurotoxins in the neurobiology of pain. Headache 43 (Suppl. 1), S2—S8 (2003).
  • Jankovic J, Vuong KD, Ashan J. Comparison of efficacy and immunogenicity of original versus current botulinum toxin in cervical dystonia. Neurology60(7), 1186–1188 (2003).

Website

  • Cui M, Khanijou S, Rubino J, Aoki KR. Botulinum toxin A inhibits the inflammatory pain in the rat formalin model. Abstracts of the 30th Annual Meeting of the Society for Neuroscience. November 4–9 New Orleans, LA, USA http://sfn.scholarone.com/itin2000/ main.html (Accessed November 2003)

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.